These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11273886)

  • 1. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
    Moll S; Nickeleit V; Mueller-Brand J; Brunner FP; Maecke HR; Mihatsch MJ
    Am J Kidney Dis; 2001 Apr; 37(4):847-51. PubMed ID: 11273886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
    Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
    Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
    J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
    Otte A; Herrmann R; Mäcke HR; Müller-Brand J
    Praxis (Bern 1994); 1999 Aug; 88(31-32):1263-8. PubMed ID: 10479965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yttrium-90 DOTATOC: first clinical results.
    Otte A; Herrmann R; Heppeler A; Behe M; Jermann E; Powell P; Maecke HR; Muller J
    Eur J Nucl Med; 1999 Nov; 26(11):1439-47. PubMed ID: 10552085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group.
    Chinol M; Bodei L; Cremonesi M; Paganelli G
    Semin Nucl Med; 2002 Apr; 32(2):141-7. PubMed ID: 11965609
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
    J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
    Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. End-stage renal disease after treatment with 90Y-DOTATOC.
    Cybulla M; Weiner SM; Otte A
    Eur J Nucl Med; 2001 Oct; 28(10):1552-4. PubMed ID: 11685499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
    Waldherr C; Pless M; Maecke HR; Schumacher T; Crazzolara A; Nitzsche EU; Haldemann A; Mueller-Brand J
    J Nucl Med; 2002 May; 43(5):610-6. PubMed ID: 11994522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of lymphocyte function following yttrium-90 DOTATOC therapy.
    Barsegian V; Hueben C; Mueller SP; Poeppel TD; Horn PA; Bockisch A; Lindemann M
    Cancer Immunol Immunother; 2015 Jun; 64(6):755-64. PubMed ID: 25822768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
    Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
    Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
    Cybulla M; Weiner SM; Otte A
    Med Sci Monit; 2002 Apr; 8(4):LE7. PubMed ID: 11951054
    [No Abstract]   [Full Text] [Related]  

  • 16. Kidney failure after treatment with 90Y-DOTATOC.
    Schumacher T; Waldherr C; Mueller-Brand J; Maecke H
    Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):435. PubMed ID: 12002721
    [No Abstract]   [Full Text] [Related]  

  • 17. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
    Cremonesi M; Ferrari M; Zoboli S; Chinol M; Stabin MG; Orsi F; Maecke HR; Jermann E; Robertson C; Fiorenza M; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Aug; 26(8):877-86. PubMed ID: 10436201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
    Forrer F; Riedweg I; Maecke HR; Mueller-Brand J
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):334-40. PubMed ID: 18480742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.
    Forrer F; Uusijärvi H; Storch D; Maecke HR; Mueller-Brand J
    J Nucl Med; 2005 Aug; 46(8):1310-6. PubMed ID: 16085587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.